Roivant and iNtRON sign licensing deal for SAL200

Roivant and iNtRON sign licensing deal for SAL200

November 20, 2018 430

Roivant Sciences and iNtRON Biotechnology have signed a $667.5m global licensing agreement for SAL200, which is an investigational biologic to treat infectious diseases caused by antibiotic-resistant staphylococci.

This licensing agreement consists of milestone payments with royalties on net sales in the low double digits.

On signing the deal, iNtRON Bio will receive a payment plus milestone payments for development, regulatory, and sales-driven events.

With this deal, Roivant also gains the option to license iNtRON Bio’s non-clinical stage, anti-Gram-positive endolysin programmes, which include anti-VRE and anti-TB biologics for an additional amount of up to $45m each.

Roivant also gets the first right of offer for anti-Gram-negative platform of iNtRON Bio. The company has set up a subsidiary for the global development and commercialisation of endolysin products from iNtRON Bio.

Image result for Roivant and iNtRON sign licensing deal for SAL200

 

The firm intends to begin a Phase II trial for SAL200 in next year.

Roivant Pharma president Mayukh Sukhatme said: “This partnership with iNtRON represents our commitment at Roivant Pharma to deliver transformational therapeutics.

“The development of novel anti-infective therapies is one of the greatest needs of our time and we hope to maximize the impact of SAL200 on public health through innovative approaches to both development and commercialisation.”

iNtRON Bio CEO Kyung Won Yoon said: “This partnership between iNtRON Bio and Roivant combines our industry-leading endolysin platform with their track record of operational excellence.

“Together we hope to ensure that physicians have better options in their armamentarium in preparation for the ‘post-antibiotic era’ on the horizon.”

A biotechnology company based in Korea, iNtRON Bio focuses on the development of bacteriophage/endolysin-based antibacterials to treat serious infections.

 

 

Information source: https://www.pharmaceutical-technology.com/news/roivant-intron-sal200/

Block ?

If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock

Complain

The user will not know who exactly sent the complaint

Delete Company

The user will not know who exactly sent the complaint

Notifications

You Have 112 readed notifications

CHATS

Select chat category

×